Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2 Negative Breast Cancer
Interventions: DRUG: Eribulin|DRUG: Cyclophosphamide|DRUG: Docetaxel
Sponsor: SCRI Development Innovations, LLC
Collaborators: Eisai Inc.